CLL Panel DeletionDuplication detection Test – Cost AED 2100.0
Are you concerned about chronic lymphocytic leukemia (CLL)? DNA Labs UAE offers the CLL Panel DeletionDuplication detection Test, a comprehensive genetic test that can provide valuable insights into this type of cancer. With a price of AED 2100.0, this test is accessible and affordable for individuals seeking accurate diagnosis and personalized treatment options.
Test Name: CLL Panel DeletionDuplication detection Test
Components: EDTA Vacutainer (2ml)
Price: 2100.0 AED
Sample Condition: Bone marrow / Peripheral blood (Transport immediately)
Report Delivery: 7-10 days
Method: MLPA
Test Type: Genetics
Doctor: Oncology
Test Department: DNA Labs UAE
Pre Test Information
CLL Panel Deletion/Duplication detection test requires a doctor’s prescription. However, it is important to note that this test is not applicable for surgery and pregnancy cases, as well as individuals planning to travel abroad.
Test Details
The CLL Panel DeletionDuplication detection test is a cytogenetic process specifically designed to identify and analyze abnormalities in the chromosome 13q14 region. This region is commonly associated with chronic lymphocytic leukemia (CLL), a type of cancer that affects the white blood cells.
Deletion and duplication of genetic material in the 13q14 region are frequently observed in CLL patients. These genetic abnormalities can have prognostic implications and significantly impact the treatment approach. To detect panel deletions or duplications, advanced laboratory techniques such as fluorescence in situ hybridization (FISH) and array comparative genomic hybridization (aCGH) are employed.
FISH involves using fluorescently labeled DNA probes that bind to specific regions of the chromosome, allowing for the visualization of deletions or duplications. On the other hand, aCGH compares the patient’s DNA sample to a reference sample, identifying differences in copy number across the genome.
The identification of panel deletions or duplications in CLL patients is crucial for risk stratification and treatment decisions. Patients with certain genetic abnormalities may have a more aggressive disease course and may require more intensive therapies. Additionally, the detection of these abnormalities can also help in monitoring disease progression and response to treatment.
Overall, the CLL Panel DeletionDuplication detection test plays a crucial role in the management of CLL patients, aiding in risk assessment, treatment planning, and disease monitoring.
Test Name | CLL Panel DeletionDuplication detection Test |
---|---|
Components | EDTA Vacutainer (2ml) |
Price | 2100.0 AED |
Sample Condition | Bone marrow \/ Peripheral blood (Transport immediately) |
Report Delivery | 7-10 days |
Method | MLPA |
Test type | Genetics |
Doctor | Oncology |
Test Department: | |
Pre Test Information | CLL Panel Deletion/Duplication detection can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad. |
Test Details |
CLL Panel Deletion/Duplication detection refers to a process used in the field of cytogenetics to identify and analyze abnormalities in the chromosome 13q14 region. This region is commonly associated with chronic lymphocytic leukemia (CLL), a type of cancer that affects the white blood cells. Deletion and duplication of genetic material in the 13q14 region are frequent genetic abnormalities observed in CLL patients. These abnormalities can have prognostic implications and impact the treatment approach. To detect panel deletions or duplications, various laboratory techniques are employed, such as fluorescence in situ hybridization (FISH) and array comparative genomic hybridization (aCGH). FISH involves using fluorescently labeled DNA probes that bind to specific regions of the chromosome, allowing visualization of deletions or duplications. aCGH, on the other hand, compares the patient’s DNA sample to a reference sample, identifying differences in copy number across the genome. The identification of panel deletions or duplications in CLL patients is essential for risk stratification and treatment decisions. Patients with certain genetic abnormalities may have a more aggressive disease course and may require more intensive therapies. Additionally, the detection of these abnormalities can also help in monitoring disease progression and response to treatment. Overall, CLL Panel Deletion/Duplication detection plays a crucial role in the management of CLL patients, aiding in risk assessment, treatment planning, and disease monitoring. |